2:I[231,["231","static/chunks/231-0fefb1d35a503081.js","669","static/chunks/app/asx/%5Bticker%5D/page-f6c15ab6b5482fb0.js"],""]
3:I[9275,[],""]
5:I[1343,[],""]
6:I[8173,["231","static/chunks/231-0fefb1d35a503081.js","410","static/chunks/410-427e639415368772.js","185","static/chunks/app/layout-cc68188960cc2107.js"],"Image"]
4:["ticker","SPL","d"]
0:["expxC_2cvqaJFzWCHYH4M",[[["",{"children":["asx",{"children":[["ticker","SPL","d"],{"children":["__PAGE__?{\"ticker\":\"SPL\"}",{}]}]}]},"$undefined","$undefined",true],["",{"children":["asx",{"children":[["ticker","SPL","d"],{"children":["__PAGE__",{},[["$L1",["$","div",null,{"className":"space-y-12","children":[["$","script",null,{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What does SPL do?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"SPL develops dendrimer technology for enhanced drug delivery in oncology, infectious diseases, and beyond.\"}},{\"@type\":\"Question\",\"name\":\"Is SPL a good investment?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"SPL offers high-risk, high-reward potential. Success in trials or partnerships could lead to significant gains, but biotech development risks are substantial.\"}},{\"@type\":\"Question\",\"name\":\"What drives SPL's share price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Clinical trial outcomes, partnership announcements, funding news, and broader biotech sector sentiment are key drivers.\"}}]}"}}],["$","section",null,{"className":"grid gap-8 lg:grid-cols-[1.6fr_0.8fr]","children":[["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"Health Care"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":["Starpharma Holdings Limited"," (","SPL",")"]}],["$","p",null,{"className":"mt-4 text-sm text-slate-300","children":"Starpharma Holdings Limited (SPL) is an Australian biotech company specializing in pharmaceuticals and life sciences. Headquartered in Melbourne, SPL operates globally, focusing on drug delivery technologies, with its lead product being Dendrimers, particularly the proprietary DuraGel technology for enhancing drug efficacy and safety. Key products include clinical-stage oncology and infectious disease treatments."}],["$","div",null,{"className":"mt-6 grid gap-4 sm:grid-cols-2","children":[["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Market Cap"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"A$172M"}]]}],["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Shares on Issue"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"N/A"}]]}]]}],["$","div",null,{"className":"mt-6 flex flex-wrap gap-3 text-xs text-slate-400","children":[["$","a",null,{"href":"","className":"rounded-full border border-white/10 px-3 py-1","children":"Company Website"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"AI coverage updated hourly"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"Data from ASX filings"}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h2",null,{"className":"font-display text-xl font-semibold","children":"Price Chart (TradingView)"}],["$","div",null,{"className":"mt-4 h-72 rounded-xl border border-dashed border-blue-500/30 bg-ink-900/40 p-6 text-sm text-slate-400","children":["Embed TradingView widget here for ","SPL",". The production version should load live pricing and technical indicators."]}]]}],["$","section",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h2",null,{"className":"font-display text-xl font-semibold","children":"AI Analysis"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm text-slate-300","children":[["$","p","SPL currently operates in a pre-revenue stage, relying on clinical trial progress and partnerships for valuation growth. Recent performance has been volatile, typical of small-cap biotechs, with a market cap of A$172M reflecting its speculative, high-risk profile. Key metrics include successful Phase I/II trials for its dendrimer-based treatments.",{"children":"SPL currently operates in a pre-revenue stage, relying on clinical trial progress and partnerships for valuation growth. Recent performance has been volatile, typical of small-cap biotechs, with a market cap of A$172M reflecting its speculative, high-risk profile. Key metrics include successful Phase I/II trials for its dendrimer-based treatments."}],["$","p","Growth prospects hinge on successful Phase III trials, potential licensing agreements, and regulatory approvals. Strategic direction emphasizes expanding the dendrimer platform into new therapeutic areas and seeking partnerships to offset development costs.",{"children":"Growth prospects hinge on successful Phase III trials, potential licensing agreements, and regulatory approvals. Strategic direction emphasizes expanding the dendrimer platform into new therapeutic areas and seeking partnerships to offset development costs."}]]}]]}],["$","div",null,{"className":"grid gap-6 lg:grid-cols-2","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-emerald-300","children":"Bull Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","Successful Phase III trial outcomes for lead dendrimer-based oncology drug, leading to regulatory approval and revenue generation.",{"children":["• ","Successful Phase III trial outcomes for lead dendrimer-based oncology drug, leading to regulatory approval and revenue generation."]}],["$","li","Strategic partnership or licensing deal with a major pharmaceutical company, validating technology and providing significant funding.",{"children":["• ","Strategic partnership or licensing deal with a major pharmaceutical company, validating technology and providing significant funding."]}],["$","li","Expansion of Dendrimers into high-growth markets such as gene therapy or personalized medicine.",{"children":["• ","Expansion of Dendrimers into high-growth markets such as gene therapy or personalized medicine."]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-red-300","children":"Bear Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","Failure in pivotal clinical trials, jeopardizing lead product pipelines and significantly reducing valuation.",{"children":["• ","Failure in pivotal clinical trials, jeopardizing lead product pipelines and significantly reducing valuation."]}],["$","li","Intensified competition in the biotech sector, particularly in dendrimer technology, reducing SPL's competitive edge.",{"children":["• ","Intensified competition in the biotech sector, particularly in dendrimer technology, reducing SPL's competitive edge."]}],["$","li","Insufficient funding to progress through clinical trials without dilutive capital raisings.",{"children":["• ","Insufficient funding to progress through clinical trials without dilutive capital raisings."]}]]}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Recent Announcements"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"font-semibold","children":"Quarterly Activities Report"}],["$","p",null,{"className":"text-xs text-slate-500","children":"Highlights production updates, capital allocation priorities, and FY guidance commentary."}]]}],["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"font-semibold","children":"Investor Presentation"}],["$","p",null,{"className":"text-xs text-slate-500","children":"Strategic outlook with market positioning and growth pipeline."}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"FAQs"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div","What does SPL do?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What does SPL do?"}],["$","p",null,{"className":"text-slate-400","children":"SPL develops dendrimer technology for enhanced drug delivery in oncology, infectious diseases, and beyond."}]]}],["$","div","Is SPL a good investment?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"Is SPL a good investment?"}],["$","p",null,{"className":"text-slate-400","children":"SPL offers high-risk, high-reward potential. Success in trials or partnerships could lead to significant gains, but biotech development risks are substantial."}]]}],["$","div","What drives SPL's share price?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What drives SPL's share price?"}],["$","p",null,{"className":"text-slate-400","children":"Clinical trial outcomes, partnership announcements, funding news, and broader biotech sector sentiment are key drivers."}]]}]]}]]}]]}],["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-semibold","children":"Key Metrics"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Share Price"}],["$","span",null,{"className":"font-semibold","children":["A$","1.22"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"1Y Performance"}],["$","span",null,{"className":"font-semibold text-red-400","children":["-4.0","%"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Market Cap"}],["$","span",null,{"className":"font-semibold","children":"A$172M"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Shares on Issue"}],["$","span",null,{"className":"font-semibold","children":"N/A"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Sector"}],["$","span",null,{"className":"font-semibold","children":"Health Care"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"IPO Date"}],["$","span",null,{"className":"font-semibold","children":"28/09/2000"}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Compare ASX Brokers"}],["$","p",null,{"className":"mt-2 text-sm text-slate-400","children":"Find the best trading platform for your needs. We review fees, features, and research tools."}],["$","div",null,{"className":"mt-4 grid gap-3 sm:grid-cols-2","children":[["$","div","AlphaTrade",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"AlphaTrade"}],["$","p",null,{"className":"text-xs text-slate-400","children":"$$0 brokerage on ETFs"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}],["$","div","MarketPilot",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"MarketPilot"}],["$","p",null,{"className":"text-xs text-slate-400","children":"Advanced research suite"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}],["$","div","Coastline",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"Coastline"}],["$","p",null,{"className":"text-xs text-slate-400","children":"Low FX fees"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}],["$","div","Harbour",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"Harbour"}],["$","p",null,{"className":"text-xs text-slate-400","children":"Pro-level charting"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}]]}],["$","p",null,{"className":"mt-3 text-xs text-slate-500","children":"Sponsored links. We may receive compensation if you open an account."}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Related Stocks"}],["$","div",null,{"className":"mt-4 space-y-4","children":[["$","$L2",null,{"href":"/asx/CSL","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["CSL",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"CSL Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","285.40"]}],["$","p",null,{"className":"text-xs font-semibold text-emerald-400","children":["9.1","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$140B"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L2",null,{"href":"/asx/PNV","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["PNV",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Polynovo Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","1.66"]}],["$","p",null,{"className":"text-xs font-semibold text-emerald-400","children":["14.7","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$2.4B"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L2",null,{"href":"/asx/1AD","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["1AD",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Adalta Limited"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","0.09"]}],["$","p",null,{"className":"text-xs font-semibold text-emerald-400","children":["37.0","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$11M"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}]]}]]}]]}]]}]]}]],null],null]},["$","$L3",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children","$4","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L5",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},["$","$L3",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L5",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},[["$","html",null,{"lang":"en","className":"__variable_6d343d __variable_49a339","children":[["$","head",null,{"children":["$","link",null,{"rel":"icon","href":"/logo.svg","type":"image/svg+xml"}]}],["$","body",null,{"className":"min-h-screen bg-ink-900 text-slate-100","children":["$","div",null,{"className":"grid-glow min-h-screen","children":[["$","header",null,{"className":"sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur","children":[["$","div",null,{"className":"mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8","children":[["$","$L2",null,{"href":"/","className":"flex items-center gap-3","children":[["$","$L6",null,{"src":"/logo.svg","alt":"ASX Desk","width":140,"height":40,"className":"h-10 w-auto","priority":true}],["$","span",null,{"className":"hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline","children":"Research Terminal"}]]}],["$","nav",null,{"className":"hidden items-center gap-6 text-sm text-slate-300 md:flex","children":[["$","$L2","/",{"href":"/","className":"transition hover:text-white","children":"Home"}],["$","$L2","/screener",{"href":"/screener","className":"transition hover:text-white","children":"Screener"}],["$","$L2","/sectors/materials",{"href":"/sectors/materials","className":"transition hover:text-white","children":"Sectors"}],["$","$L2","/news",{"href":"/news","className":"transition hover:text-white","children":"News"}],["$","$L2","/compare/BHP-vs-RIO",{"href":"/compare/BHP-vs-RIO","className":"transition hover:text-white","children":"Compare"}],["$","$L2","/about",{"href":"/about","className":"transition hover:text-white","children":"About"}]]}],["$","div",null,{"className":"hidden items-center gap-3 sm:flex","children":[["$","button",null,{"className":"rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20","children":"Premium Research"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400","children":"Open Account"}]]}]]}],["$","div",null,{"className":"flex items-center justify-between border-t border-white/5 px-4 py-3 text-xs text-slate-400 md:hidden","children":[["$","span",null,{"children":"AI market insights for ASX investors"}],["$","$L2",null,{"href":"/screener","className":"text-blue-300","children":"Screener"}]]}]]}],["$","main",null,{"className":"mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8","children":["$","$L3",null,{"parallelRouterKey":"children","segmentPath":["children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L5",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":["$","div",null,{"className":"flex min-h-[60vh] flex-col items-center justify-center text-center","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"404"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":"Page not found"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"We couldn't locate that ASX page. Try searching a ticker or visit the homepage."}],["$","$L2",null,{"href":"/","className":"mt-6 rounded-full bg-blue-500 px-6 py-3 text-xs font-semibold uppercase tracking-wide text-white","children":"Back to Home"}]]}],"notFoundStyles":[],"styles":null}]}],["$","footer",null,{"className":"border-t border-white/10 bg-ink-800/60","children":[["$","div",null,{"className":"mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8","children":[["$","div",null,{"children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"ASX Desk"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools."}],["$","div",null,{"className":"mt-4 flex gap-3","children":[["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}],["$","button",null,{"className":"rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300","children":"Download Media Kit"}]]}]]}],["$","div",null,{"className":"grid grid-cols-2 gap-6 text-sm text-slate-400","children":[["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Platform"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L2",null,{"href":"/screener","className":"hover:text-white","children":"Screener"}]}],["$","li",null,{"children":["$","$L2",null,{"href":"/news","className":"hover:text-white","children":"News & Commentary"}]}],["$","li",null,{"children":["$","$L2",null,{"href":"/about","className":"hover:text-white","children":"About"}]}]]}]]}],["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Sectors"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L2",null,{"href":"/sectors/materials","className":"hover:text-white","children":"Materials"}]}],["$","li",null,{"children":["$","$L2",null,{"href":"/sectors/financials","className":"hover:text-white","children":"Financials"}]}],["$","li",null,{"children":["$","$L2",null,{"href":"/sectors/health care","className":"hover:text-white","children":"Health Care"}]}],["$","li",null,{"children":["$","$L2",null,{"href":"/sectors/information technology","className":"hover:text-white","children":"Information Tech"}]}],["$","li",null,{"children":["$","$L2",null,{"href":"/sectors/energy","className":"hover:text-white","children":"Energy"}]}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h4",null,{"className":"font-semibold","children":"Weekly Alpha Briefing"}],["$","p",null,{"className":"mt-2 text-sm text-slate-400","children":"Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox."}],["$","div",null,{"className":"mt-4 flex flex-col gap-3 sm:flex-row","children":[["$","input",null,{"type":"email","placeholder":"you@example.com","className":"w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Subscribe"}]]}],["$","p",null,{"className":"mt-3 text-xs text-slate-500","children":"By subscribing you agree to receive marketing updates. Unsubscribe anytime."}]]}]]}],["$","div",null,{"className":"border-t border-white/10 py-6 text-center text-xs text-slate-500","children":["$","p",null,{"children":"General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results."}]}]]}]]}]}]]}],null],null],[[["$","link","0",{"rel":"stylesheet","href":"/_next/static/css/7c1fda61599f9f98.css","precedence":"next","crossOrigin":"$undefined"}]],[null,"$L7"]]]]]
7:[["$","meta","0",{"name":"viewport","content":"width=device-width, initial-scale=1"}],["$","meta","1",{"charSet":"utf-8"}],["$","title","2",{"children":"SPL share price, analysis & company profile - Starpharma Holdings Limited | ASX Desk"}],["$","meta","3",{"name":"description","content":"Latest SPL share price overview, what Starpharma Holdings Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","link","4",{"rel":"canonical","href":"https://asxdesk.com/asx/SPL/"}],["$","meta","5",{"property":"og:title","content":"SPL share price, analysis & company profile - Starpharma Holdings Limited"}],["$","meta","6",{"property":"og:description","content":"Latest SPL share price overview, what Starpharma Holdings Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","7",{"property":"og:url","content":"https://asxdesk.com/asx/SPL/"}],["$","meta","8",{"property":"og:type","content":"article"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"SPL share price, analysis & company profile - Starpharma Holdings Limited"}],["$","meta","11",{"name":"twitter:description","content":"Latest SPL share price overview, what Starpharma Holdings Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","12",{"name":"next-size-adjust"}]]
1:null
